Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 0 22 IN DEXTROSE 5 AND SODIUM CHLORIDE 0 33 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 0 22 IN DEXTROSE 5 AND SODIUM CHLORIDE 0 33 IN PLASTIC CONTAINER.
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER vs POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate provides magnesium ions, which are essential for various physiological processes. It acts as a cofactor for enzymatic reactions, stabilizes excitable membranes, and antagonizes calcium entry at the neuromuscular junction, leading to reduced acetylcholine release and muscle relaxation. In the CNS, it may act as a noncompetitive antagonist of NMDA receptors, exerting anticonvulsant effects.
Potassium is the major intracellular cation. It is essential for maintaining cell membrane potential, nerve impulse transmission, muscle contraction, and acid-base balance. Dextrose provides a source of calories and may decrease protein and nitrogen losses. Sodium chloride maintains extracellular fluid volume and osmolality.
1 to 4 g intravenously as a 5% to 20% solution, rate not exceeding 150 mg/min; dosing frequency depends on indication (e.g., preeclampsia/eclampsia: 4-5 g IV loading then 1-2 g/hr infusion; hypomagnesemia: 1-2 g IV over 1-2 hours, may repeat based on serum magnesium levels).
Administer intravenously at a rate of 100-200 mL/hour (5-10 mmol potassium/hour) based on serum potassium levels and patient tolerance. Typical adult dose: 1 liter of the solution provides 10 mEq potassium, 50 g dextrose, and 77 mEq sodium; adjust according to electrolyte needs.
None Documented
None Documented
Terminal half-life approximately 4-5 hours in normal renal function; prolonged in renal impairment (up to 40 hours).
The terminal elimination half-life of potassium is approximately 8 hours; however, potassium equilibration between intracellular and extracellular compartments takes 15-24 hours. In clinical contexts, distribution half-life is more relevant for intravenous administration.
Primarily renal (90-100% as unchanged magnesium). Less than 1% biliary/fecal.
Potassium is primarily excreted renally (>90%) as potassium ions; also undergoes minimal fecal and biliary elimination. Excretion is regulated by renal function, aldosterone, and acid-base status.
Category C
Category A/B
Electrolyte
Electrolyte